iCAD Releases Enhanced ProFound Detection Workstation Features to Streamline Mammogram Interpretation for Radiologists
19 mars 2024 09h00 HE
|
iCAD, Inc.
NASHUA, N.H., March 19, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect...
iCAD Announces Fiscal Fourth Quarter and Full-Year 2023 Financial Results
12 mars 2024 16h01 HE
|
iCAD, Inc.
Annual Recurring Revenue of $8.7 million, an increase of 15% year-over-yearFull-Year Operating Cash Flow ($5) million vs. ($12.8) million prior yearYear ending cash balance of $21.7M NASHUA, N.H.,...
iCAD Highlights Promising Clinical Data Demonstrating Ability to Reduce Breast Interval Cancer Rates and Decrease Recall Rates at ECR 2024; Showcases Additional Platform Offerings
28 févr. 2024 08h05 HE
|
iCAD, Inc.
Clinical evidence demonstrates ProFound Detection’s AI may help reduce breast interval cancer (IC) rates and decrease recall rates without additional false negatives Findings reveal substantially...
iCAD expands Board of Directors with the appointment of Dr. Hedvig Hricak, MD, PhD, (Dr.h.cᵐ)
27 févr. 2024 09h05 HE
|
iCAD, Inc.
NASHUA, N.H., Feb. 27, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably...
iCAD to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024
27 févr. 2024 08h05 HE
|
iCAD, Inc.
NASHUA, N.H., Feb. 27, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect...
iCAD to Participate in the BTIG at Snowbird: 11th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
06 févr. 2024 08h00 HE
|
iCAD, Inc.
NASHUA, N.H., Feb. 06, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect...
iCAD Expands Board of Directors with Appointment of Michael J. Doyle, FACHE as New Board Member
30 janv. 2024 08h00 HE
|
iCAD, Inc.
NASHUA, N.H., Jan. 30, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect...
iCAD Expands Executive Sales Leadership Team as Business Grows
18 déc. 2023 08h00 HE
|
iCAD, Inc.
NASHUA, N.H., Dec. 18, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader in innovative cancer-detection solutions, today announced the expansion of its sales...
iCAD’s AI-powered solutions to Help Accelerate Breast Cancer Detection in New Collaboration with GE Healthcare
28 nov. 2023 08h00 HE
|
iCAD, Inc.
Key apps from the iCAD Breast Health Suite are now integrated with GE HealthCare’s new MyBreastAI Suite*AI applications streamline workflow and support clinicians in delivering more personalized...
iCAD’s ProFound AI Can Predict 1-2 Year Risk for Breast Cancer and Reveal Insights for Heart Disease
27 nov. 2023 08h00 HE
|
iCAD, Inc.
New research presented at Radiological Society of North America annual meeting confirms ability of ProFound Breast Health Suite to predict a woman’s one to two-year risk for breast...